January 31, 2015 7:47 PM ET

Pharmaceuticals

Company Overview of Lumavita AG

Company Overview

Lumavita AG, a biopharmaceutical company, engages in the development and commercialization of novel anti-infectives for women's health. Its products include FemiFect, an antibiotic to treat infections known to cause vaginitis, such as bacteria, fungi, and protozoa; and SPK-601 that is for the treatment of human papilloma virus (HPV) and herpes simplex virus (HSV). The company markets its products through distributors. Lumavita AG was founded in 2008 and is based in Basel, Switzerland.

Engelgasse 77

Basel,  4052

Switzerland

Founded in 2008

Phone:

41 61 225 41 02

Key Executives for Lumavita AG

Chief Executive Officer
Co-Founder and Chief Scientific Officer
Director of Finance and Accounting
Director of Business Development
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Abbott Service AG Europe
Pike Pharma GmbH Europe
Novartis Pharma Schweizerhalle AG Europe
BASF Pharma (Evionnaz) SA Europe
Medena AG Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Lumavita AG, please visit www.lumavita.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.